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Introduction
Fabry disease (FD) is an X-linked disorder caused by lysosomal 
enzyme α-galactosidase A (GLA) deficiency [1], with subsequent 
intracellular accumulation of undegraded glycosphingolipids, 
mainly globotriaosylceramide (Gb3), in multiple organs [2,3]. 
Renal failure, cardiomyopathy, and peripheral and central nervous 
system alterations are the main causes of morbidity and reduced life 
expectancy [4]. FD and familial Mediterranean fever (FMF) have 
typical clinical similarities, and both diseases may progress to end-
stage renal diseases (ESRD). The similarities between the symptoms 
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of FMF and FD might lead to a diagnostic dilemma in physicians at 
countries where FMF is observed frequently [5]. Currently, treatment 
options for FD patients include long-term enzyme replacement 
therapy (ERT) in addition to supportive management [6,7]. Two 
distinct recombinant protein replacement drugs are used for the 
treatment of Fabry patients: agalsidase alfa (Replagal, Shire) and 
agalsidase beta (Fabrazyme, Genzyme), produced using different 
methods and approved for administration at different doses [6]. Both 
preparations have been shown to be safe and effective in patients 
with FD [6,8] but there are very few data on the safety of ERT during 
pregnancy [9-13]. Here we report a case of a 22-year-old woman with 
FD who received ERT with agalsidase alfa during the pregnancy.
Case Report
The patient, a 22-year-old woman, had been healthy until since 
childhood, except for peripheral neuropathic pains, hypohidrosis, 
fatigue and gastrointestinal pain. Her family history included a father 
diagnosed with FD at the age of 47 for chronic kidney disease and left 
ventricular hypertrophy. Therefore, the diagnosis of FD in the patient 
was performed at the age of 19 years old for family screening. The 
diagnosis was confirmed by molecular analysis, that showed a single 
nucleotide point mutation in heterozygosis at nucleotide c.901 C>T 
in exon 6 (p.Arg301X) of GLA gene. 
Because of the finding of mild proteinuria (500 mg/24 h), with 
a normal creatinine clearance rate (eGFR 117 mL/min/1.73 m2), she 
underwent renal biopsy, that showed the presence of typical myeloid 
or zebra bodies at the ultra-structural analysis. Therefore, the patient 
started treatment with ACE-inhibitors and ERT with agalsidase alfa 
(0.2 mg/kg every 2 weeks). The patient performed periodic follow-
up every six months, and showed a substantial amelioration of her 
symptoms and proteinuria (100 mg/24 h) 1 year after starting the 
treatment. When the patient informed us that she was pregnant, 
she immediately stopped treatment with ACE-inhibitors because 
of the high risk of fetal malformations [14] while, based on a risk/
benefit assessment, consensus was reached on continuation of ERT 
during pregnancy. The patient was fully informed and agreed to 
continue the treatment, accepting any possible risk. The dose and 
frequency of intravenous ERT remained unchanged throughout 
pregnancy and agalsidase alfa infusions were well tolerated. The 
patient was followed closely at the Department of Nephrology and 
Obstetrics, and all evaluations were performed in accordance with 
criteria for standardized follow-up of pregnancy in Italy, revealing 
no abnormalities. Prenatal diagnosis was offered, but declined by the 
patient. Patient’s clinical condition and proteinuria remained stable 
throughout the pregnancy. At a gestational age of 39 weeks, the patient 
gave birth a healthy boy via a natural delivery (birth weight 3250 g, birth 
length 48 cm, head circumference 33 cm and Apgar score 9/10/10). 
After the delivery, patient’s clinical condition remained stable and she 
continued to perform periodic follow-up for FD.
Discussion
ERT is the cornerstone of the treatment of FD [7] and recombinant 
human α-galactosidase A is available in two forms: agalsidase alfa, 
given as an intravenous infusion at a dose of 0.2 mg/kg biweekly, 
and agalsidase beta, given as an intravenous infusion at a dose of 1 
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mg/kg biweekly [4]. Studies comparing the two forms showed no 
significance [6] and current guidelines recommend that all affected 
females should be treated as soon as there are early signs of organ 
involvement (kidney, heart and/or central nervous system signs) 
consistent with FD and not fully explained by other pathology [15]. 
Despite the well-known efficacy of both preparations of ERT, there 
are very few data on the safety of ERT during pregnancy and evidence 
is limited only to case-reports [9-13] that showed no difference in the 
pregnancy outcomes with the two drugs. 
In 2005, Wendt and colleagues described the first successful 
pregnancy outcome in a 34-year-old woman who continued ERT 
with agalsidase alfa during pregnancy without any problem; at a 
gestational age of 37 weeks, the patient gave birth to a healthy boy, 
not affected by FD, after an uneventful delivery [9]. Two more 
pregnant cases receiving agalsidase alfa were described by Kalkum 
and colleagues in 2009 [10]. No reports describing a patient receiving 
agalsidase beta was available since Germain [11] and Politei [12] who 
described 2 uneventful pregnancy outcomes with agalsidase beta: 
the first author reported the case of a patient whose conception had 
presumably occurred after the second infusion of Fabrazyme [11] 
and the second reported the case of a 37-year-old woman receiving 
agalsidase beta for the last 2 years before pregnancy [12]. In both 
cases, patients’ clinical conditions remained stable throughout the 
pregnancies and they gave birth two healthy boys at a gestational age 
of 38 weeks. More recently, Senocak described 2 patients with FD 
who received agalsidase beta during their pregnancy [13] the first was 
a 26-year-old woman who started ERT with agalsidase beta when she 
was 8-week pregnant, with regression of her proteinuria, and gave 
birth to a healthy girl at week 40; the second was a 29-year-old woman 
who started her pregnancy at the 2nd month of treatment, giving 
birth to a healthy girl at 40 week.
Similarly, in Gaucher Disease, another lysosomal storage 
disorder, no effects of continuation of ERT during pregnancy had 
been reported on the mothers or the unborn children, and the ERT 
was well tolerated and maintained the therapeutic response [16].
Presently, is unclear whether ERT crosses the placental barrier 
or if the possible clearance of placental vessels has any benefit for the 
fetus. Our patient started ERT prior to conception and continuation 
of treatment during pregnancy was carefully evaluated. In fact, 
its continuation is theoretically contraindicated, given the lack of 
reproductive studies and of data on the drug labels of both ERT 
preparations. However, on the basis of the risk/benefit assessment, 
considering the well-known efficacy of ERT in the control of 
symptoms, organ involvement and quality of life, consensus was 
reached on continuation of therapy during pregnancy.
In our opinion, and supported by the findings of literature, 
pregnancy should not be a contraindication of ERT. In conclusion, 
ERT with agalsidase alfa during pregnancy seems to be well tolerated, 
with no negative effects on the mother or child.
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